{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.1","upperLimit":"14.0","value":"12.9"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"9.2","value":"7.4"},{"groupId":"OG002","lowerLimit":"7.4","upperLimit":"11.0","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"280"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization to the date of the first documented PD or death due to any cause, whichever occurs first. PFS was determined based on tumor assessment (RECIST version 1.1 criteria) as per BIRC and survival information. If a participant did not had an event at the time of the analysis cut-off or at the start of any new anti-cancer therapy, data was censored at the date of last adequate tumor assessment. PD was defined as at least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20%, the sum must demonstrate an absolute increase of at least 5 mm\\^2.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 300 mg of LGX818 orally once daily along with 45 mg of MEK162 twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG000","title":"Part 2: LGX818 300 mg QD+MEK162 45 mg BID (Combo 300)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG001","title":"Part 2: LGX818 300 mg"},{"description":"Participants of Part 1 and 2 received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, and study discontinuation, lost to follow-up or death.","id":"OG002","title":"Part 1 + Part 2: LGX818 300 mg"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants. It was planned to report combined result data of Part 1 and Part 2 for LGX818 300 mg arm.","reportingStatus":"POSTED","timeFrame":"From randomization until documented PD, initiation of new anti-cancer therapy, censoring date or death, whichever occurred first (up to 35 months)","title":"Part 2: PFS by BIRC in Combo 300 Group as Compared to LGX818 Group","type":"SECONDARY","unitOfMeasure":"Months"}